Chronic Heart Disease in Cats: Symptoms, Causes & Emerging Treatments

What Is Chronic Heart Disease in Cats?

The key takeaway: chronic heart disease is the most common cardiac problem in cats, often goes undetected for years, but is increasingly manageable when caught early.

Chronic heart disease, also called cardiomyopathy, refers to a group of long-standing disorders of the heart muscle that gradually impair its ability to pump blood and deliver oxygen to the body ^{[1, 2]}. It is a progressive condition, meaning it tends to worsen with time, and exists on a spectrum from subclinical (no outward signs) to severe clinical disease, where fluid builds up in the lungs or life-threatening blood clots form ^{[3, 4]}.

There are several phenotypic forms (different structural patterns of disease), with hypertrophic cardiomyopathy (HCM) being by far the most common, followed by restrictive cardiomyopathy (RCM), dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), and unclassified or end-stage cardiomyopathy ^{[5, 6, 2]}. Each form looks slightly different on ultrasound and behaves differently in the long term.

To standardise care, veterinarians use an ACVIM staging system (developed by the American College of Veterinary Internal Medicine) that runs from Stage A to Stage D, classifying cats from "genetically at risk" through to "refractory heart failure" ^{[7, 8]}. This system helps guide monitoring schedules and treatment decisions at each step.

Because the early stages usually produce no visible signs, screening at-risk cats can lead to earlier diagnosis. Research consistently shows that earlier detection and structured monitoring may delay progression and improve long-term outcomes ^{[5, 3]}.

Causes and Risk Factors

The key takeaway: age, breed, male sex, and being overweight all raise the odds, but mixed-breed cats still make up the majority of cases simply because they outnumber purebreds.

A known genetic cause is a mutation in the MYBPC3 gene (a gene that helps build normal heart muscle), identified in Maine Coon and Ragdoll cats, though many affected cats have no detectable mutation in any known gene ^{[8, 7]}. Breed predisposition is strong: Maine Coon, Ragdoll, Persian, British Shorthair, Sphynx, Siberian, Norwegian Forest Cat, Scottish Fold, Turkish Van, Himalayan, and Birman are all overrepresented ^{[6, 3]}.

Age is the single biggest risk factor. The prevalence of HCM rises sharply with age, reaching roughly 29–30% in cats aged 9 years and older ^[7]. Male cats are also more frequently diagnosed with HCM than females ^[6].

Obesity is a significant, modifiable risk factor. Cats with a body condition score of 6 out of 9 or greater (a 9-point body condition scoring system where 5 is ideal and 9 is severely obese) are about four times more likely to develop HCM than lean cats ^[5]. Taurine deficiency (an amino acid cats cannot make in adequate amounts) is a nutritional cause of DCM. It is now rare in cats fed complete commercial diets but remains an important historical cause ^{[9, 1]}. Mixed-breed domestic shorthairs account for the majority of cases overall, simply because of their large numbers, but purebred cats have a higher proportional risk ^[3].

Types and Stages of Chronic Heart Disease

The key takeaway: knowing your cat's type and stage is essential because it directly determines treatment, monitoring, and prognosis.

Cardiomyopathies in cats are classified by their structural and functional phenotype: HCM, RCM, DCM, ARVC, and unclassified cardiomyopathy ^[2]. Hypertrophic cardiomyopathy (HCM) is characterised by concentric thickening of the left ventricular wall without an identifiable systemic cause. It leads to diastolic dysfunction (the heart stiffens and cannot fill properly), left atrial enlargement, and a high risk of heart failure or arterial thromboembolism (a blood clot that blocks an artery, often called ATE) ^{[5, 10, 2]}.

Restrictive cardiomyopathy (RCM) features a stiff ventricular wall that impairs filling, often with severe atrial dilation and poor diastolic function, and it typically carries a grave prognosis ^{[2, 9]}. Dilated cardiomyopathy (DCM) involves thinning and weakening of the ventricular muscle, causing systolic dysfunction (the heart cannot contract effectively); most cases today are secondary to taurine deficiency ^{[9, 1]}. Arrhythmogenic right ventricular cardiomyopathy (ARVC) is defined by right ventricular thinning, dilation, and a predisposition to dangerous ventricular arrhythmias; it often presents with right-sided congestive heart failure ^{[1, 3, 9]}. Unclassified or end-stage cardiomyopathy encompasses hearts that do not fit the other categories; these cats often present with massive left atrial enlargement and clinical signs of heart failure or ATE ^{[2, 9]}.

The ACVIM staging system stratifies cats into five stages based on risk, structural changes, and clinical status ^{[7, 3, 11, 8]}:

Stage	Description
A	At risk (predisposed breed), no structural disease
B1	Preclinical (no visible signs), no or only mild left atrial enlargement
B2	Preclinical, moderate to severe left atrial enlargement
C	Current or previous clinical heart failure or ATE
D	Refractory heart failure (no longer responding to standard treatment)

Once a cat enters Stage C (clinical signs), it remains classified as Stage C even if signs resolve with treatment, reflecting the chronic nature of the underlying disease ^{[7, 11]}.

What this means for your cat: the difference between B1 and B2 is essentially the size of the left atrium, and that single measurement is what triggers the decision to start blood-thinning medication. If your cat is in B2, anti-thrombotic (clot-preventing) prophylaxis is usually recommended.

Symptoms and Signs to Watch For

The key takeaway: early chronic heart disease is silent. The most reliable warning sign at home is a rising sleeping respiratory rate.

In the early stages (A, B1, and many B2), cats are typically asymptomatic; the disease is often discovered incidentally during wellness screening or pre-anaesthetic workup ^{[1, 8, 3]}. When congestive heart failure develops, the most common presentation is left-sided heart failure, with the following signs:

• Rapid breathing (tachypnea)
• Laboured breathing (dyspnea)
• Open-mouthed breathing
• Exercise intolerance ^{[10, 3]}

Physical signs of left heart failure include increased respiratory rate and effort, cool extremities, pale or blue-tinged gums, and hypothermia (low body temperature) due to poor cardiac output (the amount of blood the heart actually pumps to the body) ^{[1, 9, 3]}. Right-sided heart failure, most characteristic of ARVC but possible in advanced disease of any type, causes fluid accumulation in the abdomen (ascites) and sometimes pleural effusion (fluid around the lungs) ^{[1, 3]}.

Arterial thromboembolism is one of the most devastating complications. It usually presents as acute hind limb paralysis or weakness with cold paws, absent pulses, and vocalisation from pain, and is most often seen with HCM and severe left atrial enlargement ^{[1, 3, 8]}. Syncope (fainting), acute collapse, or sudden death can also occur secondary to malignant arrhythmias, even in cats that previously appeared stable ^{[3, 6]}.

Nonspecific early clues such as decreased appetite, hiding, lethargy, or vomiting may precede frank heart failure and should prompt investigation ^[1]. On auscultation (listening with a stethoscope), a veterinarian may detect a gallop rhythm (an extra heart sound) or heart murmur, but up to 69% of cats with murmurs have no structural heart disease, and many cardiomyopathic cats have no murmur at all. The absence of a murmur does not rule out heart disease ^{[6, 8]}.

The most practical home monitoring tool is the sleeping respiratory rate. A rate consistently above 30 breaths per minute indicates possible fluid buildup and warrants urgent veterinary evaluation ^[1].

How Chronic Heart Disease Is Diagnosed

The key takeaway: an echocardiogram by a cardiologist is the gold standard, but several other tests are needed to build the full picture and rule out look-alike conditions.

The diagnostic evaluation begins with a thorough history and physical examination, including accurate blood pressure measurement to rule out systemic hypertension (high blood pressure throughout the body) ^{[2, 8]}. Echocardiography (cardiac ultrasound) is the gold standard for definitive diagnosis. It assesses wall thickness, chamber sizes, systolic and diastolic function, and the presence of SAM (systolic anterior motion of the mitral valve, where the valve flap gets pulled into the outflow tract and partially blocks blood flow) or intracardiac clots ^{[1, 2, 6]}.

Thoracic radiographs (chest X-rays) are essential to evaluate heart size, detect a left auricular bulge, and identify pulmonary oedema (fluid in the lungs) or pleural effusion. They also help differentiate cardiac from primary respiratory disease ^{[3, 12]}. Cardiac biomarkers, specifically NT-proBNP (a hormone released when the heart muscle is stretched) and cardiac troponin I (cTnI, a protein released when heart muscle cells are damaged), serve as screening tools. NT-proBNP aids in distinguishing moderate to severe subclinical disease from mild or normal hearts and helps differentiate cardiac vs. respiratory causes of dyspnea; cTnI indicates myocardial injury ^{[3, 6]}.

Electrocardiography (ECG) and Holter monitoring (a portable ECG worn for 24–48 hours) are used to characterise arrhythmias in cats with syncope, episodic weakness, or suspected rhythm disturbances ^{[1, 6]}. Laboratory tests (complete blood count, biochemistry, thyroid profile, taurine levels) screen for systemic conditions that can mimic or worsen cardiomyopathy, such as hyperthyroidism (overactive thyroid gland) or electrolyte disturbances ^{[1, 8]}.

Staging relies on echocardiographic left atrial size and wall thickness. Left atrial enlargement is the key parameter that differentiates Stage B1 (mild or no enlargement) from Stage B2 (moderate to severe enlargement) and guides decisions about clot-prevention medication ^{[3, 6]}. The diagnosis of congestive heart failure (Stage C) requires consistent findings of left atrial enlargement on echocardiogram and pulmonary oedema or pleural effusion on radiographs ^[12]. Genetic testing for the MYBPC3 mutation is available for Maine Coon and Ragdoll cats, but a negative result does not exclude HCM because many cases lack any known mutation ^{[7, 11]}.

Treatment Options for Chronic Heart Disease

The key takeaway: there is no cure yet, but treatment has improved dramatically, and many cats with chronic heart disease live comfortably for months to years after diagnosis.

No medication has been proven to halt or reverse the progression of cardiomyopathy before clinical signs develop. Therapy in asymptomatic stages focuses on monitoring and, when indicated, thromboprophylaxis (medication to prevent blood clots) ^{[6, 4]}. Stage A cats (predisposed breed, no structural disease) require no treatment, only regular wellness checks and consideration of future screening ^[11].

Stage B1 cats (preclinical, no remodelling) generally need no medication, with annual echocardiographic monitoring recommended. If severe dynamic left ventricular outflow tract obstruction (SAM) is present with clinical signs or a high pressure gradient, atenolol may be considered ^{[11, 6, 8]}. Stage B2 cats (preclinical, moderate to severe left atrial enlargement) should receive anti-thrombotic prophylaxis with clopidogrel once daily to reduce ATE risk. In very high-risk cats, additional anticoagulation such as aspirin or a factor Xa inhibitor (a newer type of anticoagulant that blocks a key clotting enzyme) may be added on a case-by-case basis ^{[11, 6, 8]}.

For Stage C acute congestive heart failure, immediate treatment includes oxygen supplementation, injectable furosemide (a loop diuretic that removes fluid through the kidneys), thoracocentesis (draining fluid from around the lungs with a needle) if pleural effusion is present, and stress minimisation. Intravenous fluid therapy is contraindicated in this setting ^{[11, 6]}. For Stage C chronic management, treatment includes oral furosemide (or torsemide if response is poor), an ACE inhibitor (a drug that blocks the renin-angiotensin system, which controls blood pressure and fluid balance, such as enalapril or benazepril), and continued clopidogrel. Pimobendan (a medication that strengthens heart contractions and dilates blood vessels) may be added if systolic dysfunction is present; spironolactone is an adjunct in recurrent congestive heart failure ^{[6, 11, 8]}.

Stage D (refractory heart failure) involves intensification: switching to torsemide, adding hydrochlorothiazide to create triple diuretic therapy, and including pimobendan. A continuous-rate infusion of dobutamine may be attempted for low cardiac output. Close monitoring of renal function is critical ^[6]. Treatment of DCM mirrors that of HCM for heart failure, with the crucial addition of taurine supplementation (250 mg per cat twice daily) and confirmation that the diet is nutritionally complete ^{[9, 1, 8]}. ARVC is managed with lifelong loop diuretics (drugs like furosemide that strongly promote urine production) for right-sided heart failure, with periodic thoracocentesis or abdominocentesis (draining fluid from the abdomen) often needed for recurrent effusions ^[9].

Beta-blockers such as atenolol are reserved for selected cases with severe dynamic outflow obstruction or to control ventricular arrhythmias, and should never be started in animals with uncontrolled heart failure ^{[8, 6]}.

New and Emerging Treatments

The key takeaway: the first disease-modifying therapies for preclinical chronic heart disease in cats are now in clinical trials, representing a genuine shift in outlook.

Cardiac myosin inhibitors, including mavacamten and aficamten, reduce excessive myosin-actin cross-bridging (the molecular "gripping" between heart muscle proteins) and have shown strong results in human HCM. They are now under investigation for cats to alleviate dynamic obstruction and improve diastolic function ^{[6, 8]}. Rapamycin, an mTOR inhibitor (a drug that modulates cellular growth and ageing pathways) best known from the Dog Aging Project, is in the final stages of clinical evaluation in cats through the RAPACAT trial to determine whether a delayed-release formulation can delay progression of preclinical HCM ^{[6, 8]}.

Additional small-molecule myosin inhibitors and cardiac troponin activators (such as CK-586 and nelutroctiv) are being explored and may offer further therapeutic avenues in the future ^[6]. Metabolomic and proteomic research (studies of the small molecules and proteins produced by the body) is uncovering early metabolic derangements in HCM, such as reduced fatty acid oxidation and oxidative stress, that could serve as future drug targets ^[7]. The combination of clopidogrel and the direct oral factor Xa inhibitor rivaroxaban has also been evaluated in a small case series for prevention of ATE, with no ATE events observed; however, robust evidence from larger controlled studies is still lacking ^[13].

Diet and Nutrition for Cats With Heart Disease

The key takeaway: a complete and balanced commercial diet is the foundation; supplementation is only needed in specific circumstances.

A high-quality, complete and balanced commercial diet that meets AAFCO standards (the Association of American Feed Control Officials, which sets nutritional benchmarks for pet foods) is the foundation; this ensures adequate taurine intake and prevents nutritional DCM ^[1]. Taurine supplementation is specifically indicated for confirmed DCM or when taurine deficiency is suspected, and may be continued even after recovery ^[8].

Dietary sodium restriction is recommended to reduce fluid retention and help manage congestive heart failure. High-sodium treats, human food, and salty fish should be strictly avoided ^{[1, 8]}. Maintaining optimal body weight and muscle condition is important; in cats with cardiac cachexia (muscle wasting caused by chronic disease), ensure adequate calorie and high-quality protein intake, and consider appetite stimulants if needed ^[8]. Close monitoring of body weight, appetite, and hydration helps tailor feeding strategies; unintended weight loss signals deterioration and warrants prompt intervention ^[8].

Living With and Managing Chronic Heart Disease

The key takeaway: home management is mostly about counting breaths, reducing stress, and never adjusting medication without your vet's input.

Daily monitoring of the sleeping respiratory rate is the single most important home care task. A rate consistently above 30 breaths per minute requires immediate veterinary contact ^[1]. Provide a low-stress environment: quiet spaces, hiding boxes, consistent routines, and cat-friendly handling. Avoid situations that cause anxiety or fear ^[1]. Never discontinue or adjust medications without consulting the veterinarian; abrupt withdrawal of diuretics or beta-blockers can trigger dangerous decompensation (sudden worsening of heart function) ^[1].

Administer all medications exactly as prescribed. Transdermal cardiac formulations (gels applied to the skin) are generally not recommended because systemic absorption is unreliable ^[6]. Schedule regular veterinary rechecks: asymptomatic cats need at least annual echocardiography; cats with stable congestive heart failure may need check-ups every 3 to 6 months, and more frequently after an acute episode ^{[6, 8]}.

Watch for early warning signs of worsening disease, including ^[1]:

• Increased respiratory effort
• Open-mouth breathing
• Reduced activity or hiding
• Loss of appetite
• Sudden hind leg weakness

Treat concurrent conditions such as hyperthyroidism and systemic hypertension promptly, because controlling them can significantly improve cardiac function and quality of life ^{[9, 8]}. Avoid long-acting injectable corticosteroids such as methylprednisolone acetate, and carefully evaluate any procedure or drug that could increase fluid load, as these may precipitate heart failure in predisposed cats ^[9]. Home heart rate monitoring devices can help assess response to beta-blockers and detect arrhythmias, complementing in-clinic ECGs ^[6].

Prognosis and Life Expectancy

The key takeaway: prognosis varies enormously by type and stage, but many cats with subclinical disease live for years, and even some cats in heart failure enjoy meaningful extra time.

Prognosis varies widely by cardiomyopathy type, stage, presence of heart failure or ATE, and response to therapy. Individual outcomes remain unpredictable ^{[3, 4]}. Subclinical HCM (Stages B1 and B2) carries a relatively good short-term outlook: only 7% of cats die of cardiovascular disease within one year of diagnosis, and many remain asymptomatic for years or for life ^[3].

Once a cat reaches Stage C (clinical heart failure or ATE), the prognosis becomes more guarded: with optimal management, cats with mild to moderate congestive heart failure may live months to one to two years, but severe congestive heart failure often limits survival to a few months ^{[3, 4]}. Arterial thromboembolism dramatically worsens outlook. Median survival in cats that survive the initial six hours is approximately 219 days (about seven months), and many are euthanised at presentation due to severe pain and poor prognosis ^{[12, 5]}.

DCM caused by taurine deficiency can have an excellent prognosis if taurine supplementation is started early, with full recovery possible ^{[9, 3]}. RCM is one of the most severe forms, with median survival of only 30 to 69 days in congestive heart failure, and sudden death or ATE is common ^[9]. For ARVC specifically, evidence is limited, but palliative management with diuretics and periodic fluid drainage can maintain acceptable quality of life for months to a few years, though gradual decline is expected ^[9].

Poor prognostic indicators across types include severe left atrial enlargement, refractory congestive heart failure, elevated NT-proBNP above 1500 pmol/L, hypothermia, and failure to improve with initial heart failure therapy ^{[3, 6]}. Transient myocardial thickening (e.g., following anaesthesia, trauma, or hyperthyroidism) often resolves with time or treatment of the underlying cause, carrying a much better long-term outlook than permanent cardiomyopathies ^{[3, 2]}.

Quality of Life and End-of-Life Decisions

The key takeaway: there is no single "right time," but a good quality-of-life checklist and an honest conversation with your vet make the decision clearer.

When maximal medical therapy can no longer control congestive signs and the cat experiences repeated respiratory distress or unmanageable pain, euthanasia (a painless, vet-assisted death) should be discussed as a humane option ^[4]. Cats that present with an acute saddle thrombus and severe intractable pain, or with poor short-term survival prospects, often warrant early euthanasia to prevent suffering; many owners elect this route at diagnosis ^[5].

Open communication with the veterinary team, use of a validated quality-of-life checklist, realistic budgeting for ongoing care, and proactive discussion of euthanasia criteria can help owners make timely, compassionate end-of-life decisions for cats with chronic heart disease . Palliative care for cats in the terminal phase of heart failure can preserve comfort while avoiding hospitalisation stress, using long-term oral loop diuretics and pain management. At-home oxygen supplementation has been described but evidence for its safety and efficacy in cats is very limited. Cats should be discharged once clinically stable, with home monitoring of sleeping respiratory rate (target below 30 breaths per minute) ^{[9, 8]}.

Costs of Treating Chronic Heart Disease

The key takeaway: ongoing costs add up, so build a realistic budget and check whether pet insurance can help.

Owners should establish a budget of care because lifelong management of chronic heart disease can involve significant ongoing expenses. Pet insurance may cover some diagnostics and treatments, though pre-existing condition clauses often limit coverage . The biggest one-off expense is usually the initial diagnostic workup, particularly echocardiography by a cardiologist, while ongoing costs come from repeated rechecks, lifelong medications, and periodic blood tests to monitor kidney function and electrolytes. In North America, an initial cardiology consultation with echocardiography often runs into four figures, and monthly medication costs for a single cat in heart failure typically reach the low to mid three figures. In the UK and much of Europe, costs are generally lower in absolute terms but follow a similar pattern. Always ask your clinic for an itemised estimate and discuss which tests and treatments are essential versus optional.

Similar Conditions That Can Look Like Chronic Heart Disease

The key takeaway: several common conditions can mimic or mask chronic heart disease, so they must be ruled out before settling on a diagnosis.

Systemic hypertension can cause left ventricular hypertrophy (thickening of the heart muscle wall) that mimics HCM. Accurate blood pressure measurement, often Doppler-based (using ultrasound to detect blood flow in a small artery), is essential to avoid misdiagnosis ^{[2, 8]}. Hyperthyroidism frequently induces reversible myocardial hypertrophy and can present with heart failure; thyroid testing (total T4) should always be part of the workup ^[9].

Transient myocardial thickening occurs after stressful events such as anaesthesia, trauma, infection, or pain. It resolves over weeks to months, and serial echocardiography helps distinguish it from permanent cardiomyopathy ^{[3, 2]}. Acromegaly (hypersomatotropism, a condition caused by excess growth hormone, usually from a pituitary tumour), although rare, causes myocardial hypertrophy and should be considered in diabetic cats with unexplained heart changes; diagnosis relies on elevated IGF-1 levels (insulin-like growth factor 1, a blood marker of growth hormone activity) ^[9]. Congenital cardiac malformations such as subaortic stenosis (a narrowing just below the aortic valve) can produce murmurs and hypertrophy in young cats; a detailed echocardiogram usually reveals the structural defect ^[9].

What We Still Don't Know: Gaps and Current Research

The key takeaway: the biggest unsolved problem is how to stop chronic heart disease before it starts.

There is no disease-modifying therapy for preclinical cardiomyopathy. All current treatments only manage symptoms after they appear, and developing drugs that slow progression remains a major unmet need ^{[6, 4]}. The factors that predict which subclinical cats will progress to heart failure or sudden death are poorly understood; current staging captures structural risk but not individual biological variability ^[8].

Clopidogrel, the recommended anti-thrombotic, has been shown to significantly reduce ATE recurrence compared with aspirin (approximately 36% recurrence vs. 49% at one year in the FATCAT trial), but the risk of recurrence remains substantial, so more effective and safer antiplatelet or anticoagulant strategies are still needed ^[8]. Genetic mutations explain only a fraction of HCM cases; many affected cats, even in predisposed breeds, have no identifiable mutation, indicating that unidentified genes or environmental factors contribute significantly ^{[8, 7]}. Emerging therapies such as rapamycin and myosin inhibitors are still in clinical trials; long-term safety, optimal dosing, and which subgroups benefit most are unknown ^{[6, 8]}. Beyond taurine supplementation, the role of other nutritional interventions, such as carnitine, omega-3 fatty acids, or antioxidants, in delaying disease or improving outcomes has not been prospectively studied in cats ^[8].

❓ Frequently Asked Questions